What is the latest BETA stock price?
The latest stored price for BETA is Rs 2,478.40 as of 2026-07-21.
gimli
BETA stock AI analysis
BETA Stock AI Analysis: Price, PE, 50DMA, Shareholding and Peers
BETA DRUGS LIMITED is a small-cap stock in Healthcare. This Gimli page shows the latest available BETA price, returns, 50DMA/200DMA trend, PE, ROE, ROCE, financials, shareholding pattern, and industry peers for Indian stock screening research.
Price
₹2,478.40
1W return
+7.28%
1M return
+24.53%
3M return
+88.26%
6M return
+66.07%
1Y return
n/a
Market cap
₹2,501.85 cr
PE
60.31
PB
10.22
ROE
+18.77%
ROCE
+19.16%
RSI
70.74
Turnover
₹12.68 cr
Why it can matter in screens
- Momentum: BETA is above 50DMA, below 200DMA; RSI is 70.74.
- Returns: 1D +1.60%, 1W +7.28%, 1M +24.53%, 3M +88.26%, 1Y n/a.
- Trend levels: 52W high ₹2,478.40, 52W low ₹1,030.30, off high +0.00%.
- Liquidity: latest turnover is ₹12.68 cr; volume vs 20D is +0.84%.
- Valuation/profitability: PE 60.31, PB 10.22, ROE +18.77%, ROCE +19.16%.
- Growth: 3Y sales CAGR +19.21%, 3Y profit CAGR +10.53%.
Quick Answers
Is BETA above its 50DMA and 200DMA?
BETA is above 50DMA, below 200DMA. The latest 50DMA is 1,791.48 and the latest 200DMA is n/a.
What are BETA PE, ROE and ROCE?
BETA has PE 60.31, ROE +18.77%, and ROCE +19.16% in Gimli's latest available snapshot.
How has BETA performed recently?
BETA has returned +24.53% over 1 month, +88.26% over 3 months, and n/a over 12 months in the latest stored data.
Is this stock page investment advice?
No. This page is a data snapshot for screening and research. It is not buy, sell, legal, tax, or investment advice.
Financials and Ownership
Quarterly income statement
| Period | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 93.96 cr | 20.57 cr | 9.05 cr | 8.93 |
| 2025-12-31 | 87.27 cr | 19.30 cr | 8.52 cr | 8.40 |
| 2025-09-30 | 106.38 cr | 24.30 cr | 12.22 cr | 12.10 |
| 2025-03-31 | 93.76 cr | 19.09 cr | 9.03 cr | 9.40 |
| 2024-12-31 | 88.29 cr | 17.07 cr | 8.95 cr | 9.31 |
Annual income statement
| Year | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 384.83 cr | 86.86 cr | 41.48 cr | nan |
| 2025-03-31 | 362.36 cr | 76.47 cr | 42.42 cr | 42.02 |
| 2024-03-31 | 295.71 cr | 61.21 cr | 36.44 cr | 37.90 |
| 2023-03-31 | 227.11 cr | 53.75 cr | 30.72 cr | 30.43 |
| 2022-03-31 | 125.70 cr | 26.04 cr | 14.25 cr | 24.59 |
Balance sheet
| Period | Assets | Cash | Debt | Equity |
|---|---|---|---|---|
| 2026-03-31 | 495.80 cr | 124.85 cr | 147.81 cr | 244.77 cr |
| 2025-03-31 | 436.23 cr | 147.02 cr | 138.06 cr | 197.10 cr |
| 2024-03-31 | 254.10 cr | 28.63 cr | 14.71 cr | 157.12 cr |
| 2023-03-31 | 198.42 cr | 19.16 cr | 20.33 cr | 122.88 cr |
Cash flow
| Period | OCF | FCF | Cash change |
|---|---|---|---|
| 2026-03-31 | 37.29 cr | -16.20 cr | n/a |
| 2025-03-31 | 36.17 cr | -0.69 cr | n/a |
| 2024-03-31 | 30.93 cr | 19.31 cr | n/a |
| 2023-03-31 | 23.38 cr | 5.17 cr | n/a |
| 2022-03-31 | n/a | n/a | n/a |
Shareholding Trend
| Period | Promoter | FII/FPI | DII | MF | Retail | Pledge |
|---|---|---|---|---|---|---|
| 2026-05-25 | +59.10% | +2.95% | +6.01% | +0.00% | +31.93% | +0.00% |
| 2026-03-31 | +64.63% | +1.16% | +2.15% | +0.00% | +32.06% | +0.00% |
| 2025-12-31 | +64.90% | +1.14% | +1.90% | +0.00% | +32.07% | +0.00% |
| 2025-09-30 | +66.73% | +0.90% | +0.29% | +0.00% | +32.07% | +0.00% |
| 2025-06-30 | +66.73% | +0.90% | +0.26% | +0.00% | +32.11% | +0.00% |
| 2025-03-31 | +66.73% | +0.90% | +0.17% | +0.00% | +32.20% | +0.00% |
| 2025-03-27 | +66.73% | +0.90% | +0.17% | +0.00% | +32.20% | +0.00% |
| 2024-12-31 | +66.73% | +1.15% | +0.17% | +0.00% | +31.95% | +0.00% |
| 2024-11-27 | +66.73% | +1.16% | +0.17% | +0.00% | +31.94% | +0.00% |
| 2024-09-30 | +66.73% | +1.16% | +0.16% | +0.00% | +31.95% | +0.00% |
| 2024-06-30 | +66.73% | +0.90% | +0.12% | +0.00% | +32.25% | +0.00% |
| 2024-03-31 | +66.73% | +0.32% | +0.06% | +0.00% | +32.87% | +0.00% |
| 2023-12-31 | +66.73% | +0.32% | +0.02% | +0.00% | +32.92% | n/a |
| 2023-09-30 | +66.73% | +0.32% | +0.02% | +0.00% | +32.93% | n/a |
| 2023-06-30 | +66.73% | +0.29% | +0.04% | +0.00% | +32.93% | +0.00% |
| 2023-03-31 | +66.73% | +0.29% | +0.04% | +0.00% | +32.94% | +0.00% |
| 2022-12-31 | +66.71% | +0.29% | +0.04% | +0.00% | +32.96% | +0.00% |
| 2022-09-30 | +66.71% | +0.29% | +0.04% | +0.00% | +32.96% | +0.00% |
| 2022-06-30 | +66.71% | +0.00% | +0.29% | n/a | n/a | +0.00% |
| 2022-03-31 | +66.71% | +0.00% | +0.29% | n/a | n/a | +0.00% |
Industry Peers
| Symbol | Name | Mcap | PE | ROE | 1Y |
|---|---|---|---|---|---|
| SUNPHARMA | SUN PHARMACEUTICAL IND L | 470,725.53 cr | 40.938102 | +14.71% | +15.93% |
| DIVISLAB | DIVI S LABORATORIES LTD | 194,588.48 cr | 75.774332 | +16.19% | +9.60% |
| TORNTPHARM | TORRENT PHARMACEUTICALS L | 170,600.17 cr | 78.872017 | +17.18% | +43.04% |
| APOLLOHOSP | APOLLO HOSPITALS ENTER. L | 128,349.41 cr | 65.537894 | +21.03% | +23.05% |
| CIPLA | CIPLA LTD | 115,717.42 cr | 29.815932 | +11.79% | -2.81% |
| ZYDUSLIFE | ZYDUS LIFESCIENCES LTD | 115,022.61 cr | 22.938459 | +17.93% | +17.85% |
| LUPIN | LUPIN LIMITED | 114,980.65 cr | 21.532280 | +26.83% | +30.91% |
| MAXHEALTH | MAX HEALTHCARE INS LTD | 107,095.75 cr | 74.247785 | +14.33% | -9.67% |
Try these prompts
- Analyze BETA DRUGS with valuation, momentum and industry peers
- Compare BETA with other Healthcare stocks
- Show small-cap stocks in Healthcare above 50DMA with positive 1M return
- Find Healthcare stocks with improving momentum and reasonable valuation
Related screen ideas
- View Healthcare stocks
- View small-cap stocks
- Find stocks above 50DMA
- Compare BETA with other Healthcare stocks
Data snapshot: 2026-07-21. Not investment advice.